Novavax Inc (NVAX)

[TRUISM]

Novavax Director Sells $267,130 in Stock (NVAX)
December 19th, 2014
Click For Link




Novavax (NASDAQ:NVAX) Director Gary C. Evans unloaded 46,701 shares of Novavax stock on the open market in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $5.72, for a total transaction of $267,129.72. Following the completion of the sale, the director now directly owns 313,979 shares in the company, valued at approximately $1,795,960. The transaction was disclosed in a filing with the Securities & Exchange Commission.

Shares of Novavax (NASDAQ:NVAX) traded up 0.17% on Friday, hitting $5.93. The stock had a trading volume of 626,601 shares. Novavax has a 52 week low of $3.34 and a 52 week high of $6.95. The stock’s 50-day moving average is $5.37 and its 200-day moving average is $4.78. The company’s market cap is $1.414 billion.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.01. The company had revenue of $8.20 million for the quarter, compared to the consensus estimate of $9.20 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. The company’s quarterly revenue was up 71.0% on a year-over-year basis. Analysts expect that Novavax will post $-0.32 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at JPMorgan Chase & Co. initiated coverage on shares of Novavax in a research note on Tuesday, October 7th. They set an “overweight” rating and a $7.00 price target on the stock. Analysts at Piper Jaffray raised their price target on shares of Novavax from $9.00 to $10.50 in a research note on Wednesday, September 24th. They now have an “overweight” rating on the stock. Six equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $9.42.

Novavax, Inc (NASDAQ:NVAX) is a clinical stage biopharmaceutical company.





TRUTH